Effects of the selective dopamine D-2 receptor agonist, quinpirole on sleep and wakefulness in the rat

Monti, Jaime M.; Jantos, Héctor; Fernández, Mónica

doi:10.1016/0014-2999(89)90817-0

Cited by 69 publications

(24 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous animal studies had proposed that higher dose of dopaminergic medication might inhibit sleep through action at post-synaptic D1 and possibly D2 receptors (Monti et al 1989;Laloux et al 2008). However, several open-label studies suggested that dopaminergic drugs could improve sleep dysfunction in PD (Eggert et al 2008;Honig et al 2009), and the RECOVER trial found that Rotigotine could improve nocturnal sleep disturbances and possibly dopaminergic nonmotor daytime symptoms (such as fatigue and mood) as well (Trenkwalder et al 2011).…”

Section: Discussionmentioning

confidence: 99%

Non-Motor Symptoms in Treated and Untreated Chinese Patients with Early Parkinson’s Disease

Zhang

et al. 2014

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Non-motor symptoms (NMS) are important preclinical features of Parkinson's disease (PD) and have become the leading cause of poor quality of life with disease progression. There are little data on how antiparkinsonian medications influence the NMS in PD at early stage. In this study, we explored the distribution of NMS in treated and untreated PD and investigated the association between NMS and antiparkinsonian medications in Chinese patients with early PD. Subjects were enrolled from a Chinese PD patient cohort based on 2 clinical trials. Face-to-face interviews and evaluations were performed for clinical information. NMS were compared in patients with or without antiparkinsonian treatment, and between subgroups of dopaminergic medications. Eight hundred and sixteen PD patients were enrolled in this study, of whom 428 were newly diagnosed PD. Only 5 in 646 patients who completed all these NMS measurements (0.6%) were free of NMS. PD patients with antiparkinsonian medications had a significantly higher frequency of poor sleep (p = 0.001), depression (p = 0.0001) and constipation (p = 0.0001) after adjusted gender, onset age, duration, and Hoehn & Yahr stage. Moreover, patients treated by levodopa plus dopamine agonist had a higher percentage of bad sleepers (adjusted p = 0.040), and correlation analysis revealed that Levodopa Equivalent Dose (LED) was associated with constipation (coefficient 0.146, p = 0.005). These findings suggest that although NMS exist in the prodromal stage of PD, antiparkinsonian treatment is associated with increased frequency of some NMS, which may challenge the management for PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Non-Motor Symptoms in Treated and Untreated Chinese Patients with Early Parkinson’s Disease

Zhang

et al. 2014

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Moreover, systemic administration of D1 receptor agonists and antagonists increase and decrease, respectively, time spent awake (Monti et al, 1990;Trampus et al, 1991). D2 receptor agonists exert more complex effects, likely reflecting both presynaptic and postsynaptic functions of this receptor family (Monti et al, 1989;Python et al, 1996;Lagos et al, 1998;Olive et al, 1998). When administered centrally (i.c.v.)…”

Section: Wake-promoting Actions Of Damentioning

confidence: 99%

Neural Substrates of Psychostimulant-Induced Arousal

Berridge

2006

Neuropsychopharmacol

View full text Add to dashboard Cite

Extensive research has provided substantial insight into the neurobiological mechanisms underlying the reinforcing, locomotor-activating and stereotypy-inducing actions of psychostimulants. The diverse behavioral effects of these drugs are superimposed on potent arousalenhancing actions. Psychostimulant-induced arousal is a prominent contributing factor to the widespread use and abuse of these drugs. Moreover, enhanced arousal may be a critical component of the reinforcing and other behavioral actions of these drugs. Although long overlooked, recent work begins to identify the neural mechanisms involved in psychostimulant-induced arousal. For example, microdialysis studies demonstrate a close relationship between amphetamine-induced waking/arousal and amphetamine-induced increases in norepinephrine and dopamine efflux. Additionally, it is now clear that both norepinephrine and dopamine exert robust wakepromoting actions. The wake-promoting effects of norepinephrine involve synergistic actions of a 1 -and b-receptors, whereas dopamineinduced waking involves both D1 and D2 receptors. Finally, additional studies have identified subcortical regions involved in the wakepromoting actions of both norepinephrine and amphetamine. These regions include, but may not be limited to, the medial septal area, the medial preoptic area, and the lateral hypothalamus. Combined, these and other observations indicate a prominent involvement of both norepinephrine and dopamine in stimulant-induced arousal via actions within a network of subcortical regions. Although it is clear that both norepinephrine and dopamine contribute to psychostimulant-induced arousal, the degree to which each transmitter system is necessary for the expression of stimulant-induced arousal remains to be fully elucidated.

show abstract

“…D2 receptor agonists exert more complex effects, likely reflecting both presynaptic and postsynaptic functions of this receptor family. Thus, sedation is observed after systemic administration of low dose (and possibly presynapticpreferring) D2 agonists, whereas higher doses seem to promote waking (Monti et al, 1989;Python et al, 1996;Lagos et al, 1998;Olive et al, 1998).…”

mentioning

confidence: 99%

Wake-Promoting Actions of Dopamine D1 and D2 Receptor Stimulation

Isaac

Berridge²

2003

J Pharmacol Exp Ther

107

View full text Add to dashboard Cite

Multiple ascending neurotransmitter systems participate in the regulation of behavioral state. For example, noradrenergic, cholinergic, and serotonergic systems increase EEG and, in some cases, behavioral indices of arousal. The extent to which dopaminergic systems exert a similar activating influence on behavioral state remains unclear. The current studies examined the wake-promoting actions of centrally administered D1 and D2 receptor agonists. In these studies, intracerebroventricular infusions of a D1 (SKF-82958; 2.5 and 25 nmol) or D2 (quinpirole; 40 and 140 nmol)-agonist were made into sleeping animals. The effects of these infusions on electroencephalogram/ electromyographic indices of sleep-wake state and behavior were examined. D1 agonist administration dose dependently increased time spent awake and suppressed rapid eye movement and slow-wave sleep in the 2 h immediately after infusion. D1 agonist administration also elicited modest increases in measures of locomotion and time spent grooming and eating. D2 agonist administration had similar wake-promoting actions, accompanied by modest effects on drinking and locomotion. Interestingly, D2 agonist administration also significantly increased time spent chewing on inedible material, an arousal/ stress-related behavior. Overall, these results demonstrate that dopamine contributes to the alert waking state via actions of D1 and D2 receptors. Additionally or alternatively, these results further suggest a potential involvement of dopamine receptors in the induction of high-arousal states, including stress.

show abstract

Effects of the selective dopamine D-2 receptor agonist, quinpirole on sleep and wakefulness in the rat

Cited by 69 publications

References 25 publications

Non-Motor Symptoms in Treated and Untreated Chinese Patients with Early Parkinson’s Disease

Non-Motor Symptoms in Treated and Untreated Chinese Patients with Early Parkinson’s Disease

Neural Substrates of Psychostimulant-Induced Arousal

Wake-Promoting Actions of Dopamine D1 and D2 Receptor Stimulation

Contact Info

Product

Resources

About